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Abstract
Background: PKH67 labelling was compared for classical proliferation assessment (using S phase
evaluation) to analyse the cell proliferation of 29 AML patients treated or not with various drugs.
Among these drugs, the effect of tetrapeptide AcSDKP or AcSDKP-NH2 on AML cells, stimulated
or not by cytokines, was also evaluated in order to determine (i) if AcSDKP was able to inhibit blast
cell proliferation as it inhibits haematopoietic progenitors (ii) if AcSDKP-NH2 was more stable than
AcSDKP with FBS.
Methods: For PKH labeling, cells were suspended in Diluent C, and rapidly admixed with PKH67
solution at 20 µM PKH67. Staining was stopped by addition of FBS.
Results: A good correlation between PKH67 labelling and bromodeoxyuridine incorporation was
obtained first with 6/9 patients for control cells, then for 11/17 AML patients treated with classical
antileukemic drugs (among whom 4 were also treated with AcSDKP). The effect of AcSDKP was
also studied on 7 patients. The discrepancy between both methods was essentially due to an
accumulation of cells into different cycle phases measured by BrdUrd incorporation secondary to
drug action and PKH67 labelling which measured the dynamic proliferation. This last method allows
identifying resistant cells which still proliferate. AcSDKP or AcSDKP-NH2 induced a decrease of
leukemic cell proliferation in 5/7 patients when cytokines were added (in order to stimulate
proliferation) one day after tetrapeptide AcSDKP or AcSDKP-NH2. No effect on proliferation was
noted when cytokines were added to AcSDKP-NH2.
Conclusion: PKH67 labelling method is a powerful tool for cell proliferation assessment in
patients with AML, even in cells treated by various drugs.
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The successful treatment of acute myeloid leukaemia
(AML) is frequently impeded by the development of
resistance to a wide spectrum of cytotoxic drugs and by
cell proliferation. Daunorubicin (DNR), Cytarabine
(AraC), Etoposide (VP16), Mitoxantrone (Mitox), and
Amsacrin (AMSA) are used in the treatment of AML and
can induce drug resistance [1]. Various methods are avail-
able to assess leukemic cell proliferation. Common meth-
ods for proliferation assessment, such as
bromodeoxyuridine (BrdUrd) incorporation, are corre-
lated to treatment outcome [2,3]. BrdUrd is an analogue
of thymidine and can be incorporated specifically into
DNA instead of thymidine. BrdUrd incorporation was
described, in literature, as a reference technique for cell
proliferation evaluation but is often difficult to standard-
ize [3]. Evaluation of cell distribution in each phase could
also be determined by monoparameter analysis after stoi-
chiometric DNA labelling using propidium iodide (PI)
[4]. These two methods require cell fixation and cell per-
meabilization whereas PKH dye labelling can be per-
formed on living cells.
PKH (from the author who developped these dyes: Paul
Karl Horan) are vital lipophilic, fluorescent, membrane
intercalating dyes [5]. They contain two long alkyl chains,
which allow a strong anchorage in the lipid bilayer. When
labelled cells divide, the resulting daughter cells receive
half the label, reducing the fluorescence intensity to one-
half that the parent cells. As a consequence, the prolifera-
tion of labelled cells is correlated to a decrease in fluores-
cence [6,7]. Drugs such as DNR, a fluorescent molecule,
do not interfere with PKH67 staining, when a delay (3
hours minimum) between PKH67 labelling and DNR
incubation is respected [8].
The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) iso-
lated from bone marrow was identified as a physiological
regulator of hematopoietic stem cell proliferation [9]. It
inhibits the proliferation of normal haematopoietic stem
cells and early progenitors in vivo as well as in vitro [10-
12]. However, the AcSDKP role on cell proliferation has
been discussed. Some authors have reported that AcSDKP
has no effect on the proliferative status of leukemic pro-
genitors [11] and therefore may selectively prevent the
cycle initiation of normal stem cells.
Recent studies have reported that AcSDKP is inactivated
by foetal bovine serum (FBS). It is hydrolyzed in blood by
the soluble angiotensin-I converting enzyme (ACE) [13].
A new AcSDKP (AcSDKP-NH2) was developed to increase
its stability against ACE degradation in FBS and blood.
Therefore, it was interesting to know if this analogue also
shared common properties with AcSDKP on the prolifer-
ation status of leukemic cells.
The aim of this study was to compare the proliferation of
29 AML cells from patients treated or not with cytostatic
drugs using two methods: i) dye dilution method using
PKH67 ii) or DNA content. The AcSDKP or AcSDKP-NH2
effect on cell proliferation was analyzed.
Methods
Reagents
Ficoll, PKH67 and Diluent C were given by Sigma-Aldrich
(St Quentin Fallavier, France). Daunorubicin (DNR), Ara-
cytine (AraC) and Amsacrine (AMSA) were purchased
from Roger-Bellon (Neuilly sur Seine, France). Mitox-
antrone (Mitox) was given from Léderlé (Rungis, France).
VP16 was supplied by Pierre-Fabre (Castres, France).
BrdUrd and anti-BrdUrd were purchased from Roche-
Diagnostic (Meylan, France). Cell growth medium, fetal
bovine serum (FBS), phosphate-buffered saline (PBS),
and cellulose syringe filters (0.45 mm) were purchased
from Invitrogen (Cergy-Pontoise, France).
Recombinant granulocyte-macrophage colony stimulat-
ing factor (GM-CSF) and granulocyte colony stimulating
factor (G-CSF) were used at a concentration of 20 ng/mL.
Interleukin 3 (IL3) was used at 50 ng/mL. The stem cell
factor (SCF) concentration was 25 ng/mL, and recom-
binant human ertyhropoietin (EPO) was used at 1.5 UI/
mL. All growth factors were purchased from Biosource
(California, USA).
The synthetic tetrapeptide (Acetyl-N-Ser-Asp-Lys-Pro) or
AcSDKP-NH2 was generously donated by J. Bignon and
J.Thierry respectively (Institut de Chimie des Substances
Naturelles, CNRS, France).
AML cells sampled from patients
Leukemic cells were obtained from peripheral blood or
bone marrow samples in 29 AML patients, separated on a
gradient of density (Ficoll). Only the patients samples
with more than 50% of living blasts were included in the
experiments. The 29 patients were studied as follow: 9
using BrudUrd incorporation and PKH67 labelling with-
out drug treatment, 17 using BrudUrd incorporation and
PKH67 labelling in the presence of drug or not; among the
18 patients, 4 were studied along with the remaining 3
using PKH67 labelling and DNA content analysis in order
to determine AcSDKP or AcSDKP-NH2 effect.
Cells were cultured in RPMI-1640 medium supplemented
with 10% FBS, 2 mM glutamine, 100 UI/mL penicillin,
and 100 ng/mL streptomycin, at 37°C in a humidified
atmosphere with 5% CO2.
Analysis were performed every day, as long as the percent-
age of viable cells was higher or equal to 50%. Viable andPage 2 of 14
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forward and side scatter parameters.
PKH67 labelling
PKH67 labelling was performed as described previously
[14]. Briefly, 107 cells were suspended in 1.0 mL of Dilu-
ent C, and stained by rapidly admixing with a 20 µM
working PKH67 solution, prepared by diluting 20 µl of
10-3 M ethanolic dye stock in 1.0 mL of Diluent C imme-
diately prior to staining. Final staining concentration was
therefore 10 µM PKH67 and 5 × 106 cells/mL). Staining
was stopped after 3 minutes by addition of 2 mL of FBS
and cells were washed 3 times with 5 mL of RPMI-1640
containing 10% FBS. For each sample, an aliquot of blasts
was fixed with 2% PFA at D0 and kept at +4°C in order to
maintain the original fluorescence.
BrdUrd incorporation
107 cells were cultured in complete medium for each sam-
ple. After 24 hours, 5 µM BrdUrd were incorporated in
control cells for 15 minutes at 37°C. After elimination of
excess BrdUrd by 2 washings, cells were fixed by 70° eth-
anol and maintained at +4°C during 24 hours. Revelation
of BrdUrd molecules was made by treating cells with
hydrochloric acid 4N during 15 minutes at room temper-
ature. After several washings, 20 µL of Ac anti-BrdUrd [15]
were added to control cells for 30 minutes at room tem-
perature. Ac anti-BrdUrd was revealed by Fab'2 (antibody
coupled with FITC, 0.4 µg/mL) for 30 minutes at room
temperature. Cells were labeled simultaneously with 10
µg/mL PI and treated with RNase (1 mg/mL) during 30
minutes at room temperature, then analyzed using a FAC-
SCalibur (BD Biosciences, le Pont de Claix, France) to
measure DNA content (G0/1 and G2+M phases).
Evaluation of blast proliferation following drug treatment
Blasts were collected and labeled with PKH67. Cells were
treated during four days with one or the combination of
several drugs after one day of culture: DNR, AraC, AMSA,
VP16, and Mitox, at a concentration of 10-6 M. These con-
centrations are commonly used in therapy.
AcSDKP effect on proliferation of cells (stimulated or not 
by cytokines)
2.106 labelled with PKH67 were seeded in 25 cm2 culture
dishes numbered as described below:
Sample 1: PKH67 labelled cells without the mixture of
cytokines in complete medium at 37°C.
Sample 2: PKH67 labelled cells were cultured with
cytokines in complete medium at 37°C (G-CSF, IL3, SCF,
GM-CSF, and EPO).
Sample 3: cells with cytokines and 10-9 M AcSDKP-NH2 in
complete medium at 37°C.
Sample 4: cells without cytokines and 10-5 M AcSDKP in
complete medium at 37°C.
Sample 5: cells without cytokines and 10-9 M AcSDKP in
complete medium at 37°C.
Sample 6: cells without cytokines and 10-9 M AcSDKP-
NH2 in complete medium at 37°C.
Sample 7: cells without cytokines and 10-9 M AcSDKP-
NH2 in complete medium at 37°C. After a day of culture,
cells contained in samples 4, 5, and 6 were washed and
cytokines were added to the complete medium.
The tetrapetide AcSDKP concentrations used upper are
known to be active.
DNA content analysis
The cell cycle was evaluated with the Cycle Test™ kit (BD-
Biociences, Le Pont de Claix, France). Briefly, cells from
patients were incubated with trypsin in a spermine tet-
rahydrochloride detergent buffer for 10 min at room tem-
perature. Trypsin inhibitor and ribonuclease A were added
for 10 min without washing. Finally, PI was added and
incubated for 10 min, then cells were immediately ana-
lyzed by flow cytometry and distribution of cells in each
phase was evaqluated using Modfit software (Verity soft-
ware). Since both tetrapeptide could induce an increase of
cells in G0/1 phase with the Cycle Test™ kit was used
because it was easier than Brdu incorporation to evaluate
few modification in cell cycle repartition.
Flow cytometry analysis
Mean fluorescence intensity per cell was measured using a
FACSCalibur flow cytometer (BD Biosciences, Le Pont de
Claix, France) equipped with an air-cooled argon ion laser
emitting 15 mW at 488 nm and a photodiode laser emit-
ting 10 mW at 635 nm. PKH67 and FITC fluorescence
were collected with a 530 ± 30 nm band-pass filter; PI flu-
orescence was collected with a 585 ± 44 nm band-pass fil-
ter. 50,000 events were acquired with the CellQuest
software (BD Biosciences, Le Pont de Claix, France). Elec-
tronic compensation settings for FITC and PI were FL1-
FL2 = 10% and FL2-FL1 = 35%; and FL1-FL2 = 8% and
FL2-FL1 = 30% for PKH67/PI. Kolmogorov Sminov statis-
tical test (K/S test) was used to point out difference
between PKH fluorescence histograms. Differences
between histograms were considered as statistical signifi-
cant when p was under 0.001.Page 3 of 14
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We compared blast proliferation with two methods: a ref-
erence method (BrdUrd incorporation) and a dye dilution
method (PKH67 labelling), in order to validate the use of
PKH for proliferation assessment of living AML cells.
Table 1 shows the cell cycle distribution and the mean
PKH67 fluorescence of cells from 9 patients. Fluorescence
ratio is, PKH67 fluorescence at D0 divided by PKH67 flu-
orescence at D4 (D0/D4). Three different groups could be
described according to the proliferation rate determined
by PKH67 decrease and BrdUrd incorporation i) first
group with proliferation corresponding to PKH67
decrease and an S phase superior to 4% ii) second group
with low S phase (1%) and PKH67 ratio under 1.2 and iii)
a third group with a discordance between S phase and
PKH67 decrease. Using the Kolmogorov Sminov test we
showed that with a PKH67 fluorescence ratio at 1.21 there
was a significant difference between histograms [p < 0.001
for patients (Lio., Pi., Tr., Gr.)] but not below this value.
We considered that cells proliferated when PKH67 fluo-
rescence ratio was superior to 1.21. In the first group of
patients, (Lio., Pi., Tr., Gr.) PKH67 fluorescence ratios
were 2.96, 1.37, 1.39, 1.29 respectively (table 1) and
showed a cell proliferation correlated to the S phase frac-
tion (30% to 4%) (Figure 1a).
In the second group, patients Dun and Br (Figure 1b)
showed a low decrease of PKH67 fluorescence, with a flu-
orescence ratio (1.15 and 1.16) respectively at D0/D4. The
cell cycle analysis showed that 1% of the cells was in S
phase (Figure 1b).
In the third group, the S phase ranged from 8 to 11% but
the PKH67 ratio ranged from 1.06 to 1.16. These 3
patients showed a discrepancy between PKH67 fluores-
cence, revealing an interruption of proliferation and S
phase (Figure 1c).
Evaluation of blast proliferation treated with various drugs 
(Table 2)
In this part of experimentation, 17 patients were analysed.
According to the initial results shown in Table 1 and the
K/S test, three groups were identified: (i) cells from 4
patients which still underwent proliferation even after
drug treatment (ii) cells from 6 patients which were more
or less sensitive to one or more drugs associated with
interruption of proliferation, and (iii) 7 patients with no
spontaneous proliferation.
Cells from patient Gi presented a moderate spontaneous
proliferation (PKH67 ratio at 1.4 and 8% of cells in S
phase) (Figure 2). When cells were treated with AraC,
DNR, or both no decrease of PKH67 ratio was noted.
Small modifications of cell cycle phase distribution were
seen essentially with DNR or DNR + AraC with an accu-
mulation in G2+M phase.
For the cells of patient Lh, a decrease of the PKH67 ratio
compared to the control (3.7) was noted for AraC (2.32),
DNR (2.09), or combination of both (1.92) but cells still
underwent proliferation. When cells were treated with
AraC a moderate accumulation was seen in the S phase
(39%) and an accumulation in G2+M phase for DNR
(30%) or DNR+ AraC (24%). For both patients, Da and
Go, no accumulation was noted in one of the cell cycle
phases but with AraC a moderate decrease of proliferation
kinetics was pointed out by a decrease of PKH67 fluores-
cence ratio (1.4 and 1.3 respectively) compared to the
control (1.6).
In the second group Sat, Le, Fo (figure 3), and Ko cells had
spontaneous proliferation but each drug interrupted pro-
liferation. More often AraC induces an accumulation in
G1 or S phase and the others drugs, Amsacrine, daunoru-
bicine, or VP16 induced an accumulation in G2+M. When
Table 1: Comparison between BrdUrd incorporation asociated with DNA content (% of cell in cell cycle) at day 4 and PKH67 labelling 
ratio {PKH fluorescence intensity (a.u.) at Day 0 by PKH fluorescence intensity at Day 4} in 9 AML patients.
Patients Cell cycle Cell proliferation
G0/1% S% G2+M % D0 (a.u.) D4 (a.u.) PKH ratio
Lio 47 30 23 579 194 2.96
Pi 72 10 18 1966 1424 1.37
Tr 66 11 23 1851 1324 1.39
Gr 76 4 20 1988 1324 1.21
Dun 64 1 35 4821 4138 1.16
Br Relapse 76 1 23 3960 3438 1.15
Li 69 11 20 3020 2834 1.07
Ga 81 9 10 1995 1853 1.06
To 69 8 23 1444 1257 1.16Page 4 of 14
(page number not for citation purposes)
BMC Cancer 2005, 5:120 http://www.biomedcentral.com/1471-2407/5/120Comparative flow cytometry analyses of percentage of cells in S phase, using BrdUrd incorporation and PKH67 labelling {PKH fluorescenc  intensity (a.u.) at Da  0 / PKH fluorescence inte sity ( .u.) at Day 4}Figure 1
Comparative flow cytometry analyses of percentage of cells in S phase, using BrdUrd incorporation and PKH67 labelling {PKH 
fluorescence intensity (a.u.) at Day 0 / PKH fluorescence intensity (a.u.) at Day 4}. Figure 1a patient Pi, Figure 1b patient Dun, 
Figure 1c patient Ga.Page 5 of 14
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BMC Cancer 2005, 5:120 http://www.biomedcentral.com/1471-2407/5/120Table 2: Comparison between BrdUrd incorporation and PKH67 labelling in 17 AML patients treated with various drugs (DNR, AraC, 
VP16, Mitox, and AMSA). Percentage distribution of patient cells in each cell cycle phase obtained by BrdUrd incorporation and 
PKH67 labelling ratio at day 4 (PKH fluorescence intensity at Day 0 by PKH fluorescence intensity at Day 4).
GI Control AraC DNR AraC + DNR
G0/1 89 88 74 72
S 8 6 8 4
G2+M 3 6 18 24
PKH ratio 1,4 1,35 1,37 1,25
Lh Control AraC DNR AraC + DNR
G0/1 57 53 54 53
S 33 39 16 23
G2+M 10 8 30 24
PKH ratio 3,7 2,32 2,09 1,93
Da Control AraC VP16 Mitox AraC + VP16 + 
Mitox
G0/1 74 76 66 73 71
S 7 10 10 12 17
G2+M 19 14 24 15 12
PKH ratio 1,6 1,4 1,4 1,5 1,4
Go Control AraC VP16 Mitox AraC + VP16 + 
Mitox
G0/1 60 64 85 71 75
S 16 10 4 8 2
G2+M 24 26 11 21 23
PKH ratio 1,6 1,3 1,6 1,6 1,3
Sat Control AraC VP16 Mitox AraC + VP16 + 
Mitox
G0/1 82 87 89 89 89
S 14 7 4 1 1
G2+M 4 6 7 10 10
PKH ratio 1,7 1,1 1,1 1,1 1,1
Le Control AraC VP16 Mitox AraC + VP16 + 
Mitox
G0/1 70 61 56 77 77
S 14 19 16 2 1
G2+M 16 20 28 21 22
PKH ratio 2,3 1,12 1,07 1,05 1,05
Fo Control AraC AMSA DNR DNR+AraC+AMSA
G0/1 81 75 90 71 90
S 14 20 2 6 2
G2+M 5 5 8 23 8
PKH ratio 1,7 1,1 1,18 1,18 1,18
Ko Control AraC DNR VP16 AraC+DNR+VP16
G0/1 71 80 70 74 76
S 13 2 8 4 3
G2/M 16 18 22 22 21
PKH ratio 1,5 1,05 1,13 1,04 1,06
Sa Control AraC DNR AraC+DNR
G0/1 56 71 76 76
S 32 10 9 5
G2+M 12 19 17 19
PKH ratio 3 1,4 1,1 1,12
Na Control AraC DNR AraC+DNR
G0/1 65 74 57 73
S 31 21 1 23
G2+M 4 5 42 4
PKH ratio 3 2,5 1,13 1,11
Pa Control AraC DNR AraC+DNR
G0/1 89 90 87 89
S 3 1 1 1
G2+M 8 9 12 10
PKH ratio 1,18 1,1 1,1 1,1Page 6 of 14
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phase was not obvious. For patients Sa and Na, treatment
with AraC induced a decrease of proliferation shown by a
PKH67 fluorescence ratio decrease, 1.4 and 2.5 respec-
tively compared to 3 for the control. As for other patients
in the group, DNR interrupted the proliferation with a
PKH ratio under 1.2. In the third group no spontaneous
proliferation was noted "a fortiori" under treatment.
The evaluation of AcSDKP on blast proliferation 
stimulated or not by cytokines (Table 3)
We used the PKH67 assay and Cycle test from BD to assess
proliferation on blasts incubated with cytokines, AcSDKP
or AcSDKP-NH2.
In this experiment, two groups of patients could be indi-
vidualized: three patients underwent spontaneous prolif-
eration (Be, Dur, Ko), and the four others (Pa, Ph, Al, Av)
underwent proliferation only after cytokine stimulation.
The proliferation of cells from patient Be was not more
stimulated by adding cytokines compared to the control
and no effect of AcSDKP or AcSDKP-NH2 was noted on
PKH67 fluorescence ratio or on the cell cycle phase. Cells
obtained from Dur patient were stimulated by cytokines
and an increase of proliferation was noted according to
the increase of PKH67 fluorescence ratio (1.5 compared to
the control 1.2) and no effects of AcSDKP or AcSDKP-
NH2 was noted on cell cycle phase or PKH67 fluorescence
ratio. Cells from patient Ko were stimulated by cytokines
but if AcSDKP or AcSDKP-NH2 was added a day before
cytokines (sample 3) cell proliferation was interrupted
along with a decrease of the S phase associated with an
increase of G0/1 phase and a decrease of PKH67 fluores-
cence ratio (1 for sample 4, 1.12 for sample 5, 1.11 for
sample 6 compared to the control 1.49 sample 2).
In the second group, cells from patients Pa and Ph (Figure
4) underwent proliferation after cytokine stimulation but
if AcSDKP or AcSDKP-NH2 was added a day before add-
ing cytokines a slow decrease of proliferation was noted
(0.2 in the fluorescence ratio in sample 4,5,6 compared to
the ratio of sample 2 or 3). No obvious difference was
noted in the proportion of S phase in the various samples.
For the two last patients (Al and Av) AcSDKP or AcSDKP-
La Control AraC DNR AraC+DNR
G0/1 83 85 60 80
S 11 7 3 13
G2+M 6 8 37 7
PKH ratio 1,02 1,01 1,1 1,1
Luu Control AraC DNR AraC+DNR
G0/1 86 82 86 85
S 1 1 2 3
G2+M 13 17 12 12
PKH ratio 1,1 1,12 1,13 1,12
Av Control AraC DNR AraC+DNR
G0/1 68 65 80 68
S 20 16 13 15
G2+M 12 19 7 17
PKH ratio 1,09 1,07 1,08 1,1
Ph Control AraC DNR AraC+DNR
G0/1 74 75 77 79
S 1 2 3 1
G2+M 25 23 20 20










PKH ratio 1,19 1,18
Table 2: Comparison between BrdUrd incorporation and PKH67 labelling in 17 AML patients treated with various drugs (DNR, AraC, 
VP16, Mitox, and AMSA). Percentage distribution of patient cells in each cell cycle phase obtained by BrdUrd incorporation and 
PKH67 labelling ratio at day 4 (PKH fluorescence intensity at Day 0 by PKH fluorescence intensity at Day 4). (Continued)Page 7 of 14
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Comparative flow cytometry analyses of percentage of cells in S phase using BrdUrd incorporation and decrease of PKH67 flu-
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interrupted the proliferation with a PKH67 fluorescence
ratio and a percentage of S phase close to 1.
Discussion
This study had for aim to compare cell proliferation of 29
AML patients by two methods i) S phase evaluation and
DNA content for proliferation assessment and ii) PKH67
labelling to monitor proliferation of living blast treated or
not cytostatic drugs or AcSDKP a regulator of stem cells.
The proliferation assessment, using BrdUrd incorporation
and PKH67 labelling, was carried out on 9 AML patients,
7 of whom had been recently diagnosed and the other 2
were relapsing. In order to compare results, the K/S test
was applied to point out statistical difference between
PKH67 fluorescence histograms. Results were significant
when the ratio of the PKH67 histograms fluorescence was
above 1.2. In the first group of patients, the proliferation
was highly significant identified by BrdUrd incorporation
and by a decrease of PKH67 fluorescence. These results
Table 3: Comparison of blast proliferation by cell cycle analysis using PI labelling and PKH67 labelling (PKH fluorescence intensity 
(a.u.) at Day 0 / PKH fluorescence intensity (a.u.) at Day 4) in 7 AML patients stimulated or not by mixture of cytokines and incubated 
with a tetrapeptide AcSDKP (amide or not). Sample 1: PKH67 labelled cells cultured without the mixture of cytokines. Sample 2: 
PKH67 labelled cells cultured with the mixture of cytokines. Sample 3: cells with cytokines and AcSDKP-NH2 in 10-9 M. Sample 4: cells 
incubated with AcSDKP in 10-5 M to which cytokines were added after one day of culture. Sample 5: cells incubated with AcSDKP in 
10-9 M in which cytokines were added after one day of culture. Sample 6: cells incubated with AcSDKP-NH2 in 10-9 M to which 
cytokines were added after one day of culture. Sample 7: cells without cytokines and AcSDKP-NH2 in 10-9 M.
Patients Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7
Be
PKH ratio 1.24 1.25 1.26 1.27 1.28 1.3 1.26
G0/1 82 88 78 83 80 81 86
S 9 8 10 8 9 7 8
G2+M 9 4 12 9 11 12 6
Dur
PKH ratio 1.2 1.5 1.51 1.49 1.48 1.51 1.25
G0/1 87 78 82 81 81 81 90
S 6 11 8 9 8 8 6
G2+M 7 11 10 10 11 11 4
Ko
PKH ratio 1.51 1.49 1.50 1 1.12 1.11 1
G0/1 90 87 90 94 97 96 96
S 7 6 7 1 1 2 1
G2+M 3 7 3 5 2 2 3
Patients Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7
Pa
PKH ratio 1.18 2.01 2.1 1.8 1.75 1.75 1.13
G0/1 86 73 70 71 70 73 90
S 3 17 17 18 19 19 5
G2+M 11 10 13 11 11 8 5
Ph
PKH ratio 1.18 1.5 1.5 1.31 1.32 1.33 1.11
G0/1 85 78 82 83 76 83 87
S 2 12 12 9 11 9 2
G2+M 13 10 6 8 13 8 11
Al
PKH ratio 1 1.37 1.25 1.01 1.09 1.07 1
G0/1 95 83 89 93 94 91 92
S 1 8 5 1 1 1 1
G2+M 4 9 6 6 5 8 7
Av
PKH ratio 1.1 1.6 2 1.1 1.09 1.02 1
G0/1 92 66 63 90 89 90 94
S 1 16 17 1 1 1 1
G2+M 7 18 20 9 10 9 5Page 10 of 14
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and proliferation rate. In the second group, no objective
proliferation was shown either with PKH67 labelling or S
phase. In the third group a discrepancy was noted
between the S phase evaluation and proliferation using
PKH67 labelling with high S phase and no significant pro-
liferation with PKH67 labelling, The discrepancy between
the two methods can be explained by the fact that BrdUrd
incorporation associated to the measure of the DNA con-
tent, allows to estimate cell distribution in various phases
like a snapshot, as opposed to PKH67 which measures cell
division. The evaluation of dynamic proliferation, using
BrdUrd incorporation, would require using the "pulse –
chase" method which is time-consuming and difficult to
set-up [16].
The correlation between PKH67 labelling and the rate of
S phase cells had to be validated when cells are cultured
with cytostatic drugs. Indeed out of 17 AML patients,
treated with drugs, 11 showed a good correlation between
the S phase percentage of cells and the decrease of PKH67
fluorescence. In the first group of patients (4 cases), a sig-
nificant proliferation of cells was observed when cells
were treated with various drugs. This proliferation of cells
treated by DNR, VP16, Mitox could be due to ATP binding
cassette proteins such as Pgp, MRP, and BCRP [17-19].
Pgp, MRP, BCRP are known to extrude DNR, VP16, and
Mitox. The proliferation of cells treated by AraC could be
explained by spliced deoxycytidine kinase [20]. F.
Lacombe et al., [2], reported that a minimum of 3% of
cells in phase S was necessary to show a significant differ-
ence, in a study of DNA synthesis inhibition of by AraC.
These results are correlated to our results obtained with
the K/S test. AraC, a drug often used in therapy [21], was
described in literature as an antimetabolite involving the
S phase accumulation of cells [22,23].
In the second group, discrepancies were seen between the
percentage of S phase and the PKH67 fluorescence ratio in
the presence of AraC, in two cases. The S phase percentage
was superior to 20% with a BrdUrd/FITC and PI
biparametric analysis. The PKH67 fluorescence histogram
did not reveal any cellular proliferation. In these cases,
cells seemed to accumulate in phase S. The same profile
was observed when cells were treated with the DNR+AraC
mixture. Both drugs were in competition and only AraC
dominated, because an accumulation of cells was
obtained in phase S and not in phase G2+M. We did not
observe cumulative effects between these two drugs. VP16
and AMSA are inhibitors of topo-isomerases II and we
observed a low decrease of PKH67 fluorescence in 11
cases, thus a low rate of proliferation correlated to the S
phase percentage of cells. We did not observe any modifi-
cation of cell cycle distribution in the presence of these
drugs. These two drugs were reported as inducing cell
accumulation in G2+M [24,25].
We thus studied a possible effect of the tetrapeptide AcS-
DKP or the amide AcSDKP (which was supposed to be
more stable) on proliferation of AML blasts, previously
stimulated or not by cytokines. AcSDKP isolated from
bone marrow was identified as a physiological regulator
of cell proliferation [9]. AcSDKP is known to inhibit cell
proliferation of normal haematopoietic in vivo and in vitro
[10,26]. However, it was described as being ineffective on
the proliferation of leukemic cells [27] and thus it could
selectively prevent the cell cycle initiation. It was also
described as a protector of normal haematopoietic human
cells, against the toxic effects of drugs, and the effects of
radiotherapy [28-31]. It has no effect on the growth and
DNA synthesis of HL60 leukemic cells [27]. The biological
properties of AcSDKP and the absence of antiproliferative
activity on leukemic cells suggest that possible therapeutic
applications, such as the protection of hematopoietic
cells, could be used in association with chemotherapy.
The Institute of Chemistry of Natural Substances (CNRS,
Gif-sur-Yvette, France.) developed a tetrapeptide amide to
limit degradation by an ACE enzyme when cells are cul-
tured with FCS or blood [32]. We demonstrated that there
was no difference between the tetrapeptide amide and the
natural tetrapeptide. This could be explained by the fact
that the medium used for the culture of blastic cells con-
tained only 10% of FCS. AcSDKP had no effect on the pro-
liferation of stimulated cells in 5 patients [27], as well as
on leukemic HL60 and K562 cells lines, and on CML cells
[31,32]. We observed a low rate of, or an inhibition of
proliferation in 3 patients when cytokines were added one
day after AcSDKP. M Smeets et al. [33] reported that
"noncycling" progenitors, whether normal or leukemic,
presented a relatively increased level of MDR protein
expression. We probably modified the expression of
resistant proteins when we activated the proliferation of
these cells, by a decrease of resistant protein expression. P
Te Boekhorst et al., [34] showed the existence of a relation-
ship between the Pgp protein and a high fraction of cells
in phase S. They showed that high S phase was frequently
associated with the expression of multidrug resistance
proteins and poor prognosis, in acute myeloid leukaemia.
Conclusion
Our study more frequently demonstrated a good correla-
tion between PKH 67 fluorescence decrease and propor-
tion of S phase obtained by BrdUrd incorporation. We
observed a discrepancy when cells were blocked in one of
the cell cycle phases and demonstrated the power of
PKH67 labelling to follow proliferation even when cells
were treated with drugs. This method could be applied to
sort proliferating cells growing with drugs and to deter-
mine their chemoresistant protein profiles. We alsoPage 12 of 14
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compared to AcSDKP since both are able to modify blast
cell proliferation which prevents using them in therapy.
Abreviations
PKH: Paul Karl Horan, BrdUrd: bromodeoxyuridine, PI:
propidium iodide, AcSDKP: tetrapeptide acetyl-N-Ser-
Asp-Lys-Pro, NH2AcSDKP : tetrapeptide acetyl-N-Ser-Asp-
Lys-Pro amide, DNR: Daunorubicin, AraC: Aracytine,
AMSA: Amsacrine, Mitox: Mitoxantrone, VP16:
Etoposide.
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